Skip to main content
. Author manuscript; available in PMC: 2016 Apr 8.
Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):161–169. doi: 10.1097/QAI.0b013e3182427029

TABLE 2.

Summary of the Clinical Management Concerns When Treating HIV-Infected Children

Area Management Issues Requiring Research
Neurocognitive development Children with HIV accelerate their neurologic development after starting HAART, but they do not catch up with other children
Neurocognitive development in HIV-exposed but uninfected children is also below normal and needs further study
The socioeconomic and medical reasons for residual developmental delay in HAART-treated children remains to be delineated
Bone growth HAART in general, as well as specific antiretroviral agents, has been associated with subnormal bone mineral content
Children may be especially vulnerable to these effects
A major confounding factor is the worldwide deficiencies in calcium and vitamin D
Metabolic abnormalities HAART initiation is associated with decreases in inflammatory cytokines
Children on HAART nevertheless experience high rates of fat wasting, insulin resistance, dyslipidaemia and hyperlactataemia
High cholesterol levels may lead to cardiovascular disease, but aggressive lipid management is lacking in children
HIV/TB coinfection Concurrent HAART improves the response to TB therapy, but TB therapy can have negative effects on HAART effectiveness and toxicity
Drug-drug interactions and overlapping toxicities pose challenges to concurrent treatment of HIV and TB
Pharmacokinetic data on the drug-drug interactions are sparse in children
Data on management of TB and malnutrition, extrapulmonary disease, drug resistance and IRIS in children are very limited
HIV/Malaria coinfection HIV’s effect on childhood malaria is unclear
There is only limited paediatric data on PK and toxicity interactions between antiretroviral and antimalarial agents
Some HAART components may be active against malaria, but this requires further study
Malnutrition Malnutrition may interfere with absorption of HAART drugs
Malnourished children have relatively poor outcomes after initiating HAART, but there are no long-term data in this area
Researchers have not developed optimal antiretroviral/nutritional strategies for malnourished children